Welcome to our dedicated page for OKYO Pharma SEC filings (Ticker: OKYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OKYO Pharma Limited’s SEC filings document foreign-private-issuer reports on Form 6-K for a clinical-stage biopharmaceutical company with ordinary shares listed on Nasdaq. The disclosures cover urcosimod clinical and regulatory updates for neuropathic corneal pain, scientific-meeting materials, and descriptions of the company’s focus on inflammatory eye diseases and other ocular disorders.
The filing record also includes capital-structure and financing disclosures tied to Form F-3 registration statements, ordinary-share offerings, underwriter option exercises, and insider share purchases. These records present formal updates on the company’s securities, ownership activity, incorporated exhibits, and material announcements furnished under Exchange Act Rule 13a-16.
OKYO Pharma Ltd’s chief financial officer, Keeren Rameshchandra Shah, reports his existing equity stake in the company. He holds 16,667 shares of common stock directly. The filing also lists multiple option awards over common stock, including grants for 31,250 shares at a 1.50 exercise price expiring in 2035 and 25,193 shares at a 2.13 exercise price expiring in 2033.
OKYO Pharma Ltd filed a Form 3 showing that Chief Executive Officer Robert John Dempsey holds four stock option positions over its common stock. Each option position relates to 400,000 shares of common stock at an exercise price of $2.2300 per share.
The options have staggered exercise dates on January 2, 2027, January 2, 2028, January 2, 2029, and January 2, 2030, and all are scheduled to expire on January 2, 2036. The filing records these as existing holdings rather than new market transactions.
OKYO Pharma filed a report highlighting the expansion of its Scientific Advisory Board with the appointment of ophthalmology expert Marta Sacchetti, MD, PhD. She brings extensive experience in corneal and ocular surface diseases and prior leadership as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceutici.
The filing reiterates the company’s focus on neuropathic corneal pain (NCP) and inflammatory eye diseases, centered on its investigational drug Urcosimod. Urcosimod is the first therapy to receive an IND specifically for NCP and has Fast Track designation from the U.S. FDA. OKYO notes positive pain-reduction data from a randomized, placebo-controlled, double-masked Phase 2 NCP trial involving 18 patients, and prior statistical significance in multiple endpoints in a 240‑patient Phase 2 dry eye disease study. The company recently completed a Phase 2 NCP trial and plans a 150‑patient Phase 2b/3 multiple-dose study of Urcosimod for NCP in the first half of the year.
OKYO Pharma Ltd amendment to a Schedule 13G/A states that Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen each report 0% beneficial ownership of Ordinary Shares as of the close of business on 03/31/2026. The filing lists the reporting persons' business address and CUSIP G6724L116.
OKYO Pharma LTD disclosure: Woodline Partners LP reports beneficial ownership of 3,652,190 shares of Ordinary Shares, representing 7.0% of the class based on an aggregate of 52,479,257 Ordinary Shares described in the filing. The shares are held on behalf of the Woodline Fund.
The filing states Woodline has sole voting and sole dispositive power over the 3,652,190 shares. The disclosure is formatted as a Schedule 13G beneficial-ownership statement and is signed by the reporting person’s GC and CCO.
OKYO Pharma Ltd Schedule 13G: Sirenia Capital Management and Alex Silverstein report joint beneficial ownership of 4,054,054 Ordinary Shares, representing 7.7% of the class. The filing bases the percentage on 52,479,257 Ordinary Shares outstanding as calculated from issuer disclosures.
The filing states the Sirenia Fund holds the shares and has the right to receive dividends or proceeds on more than 5% of the class. Ownership is reported as shared voting and dispositive power of 4,054,054 shares.
OKYO Pharma is highlighting its eye disease program through upcoming scientific meetings and recent clinical data. The CEO will present at Eyecelerator on May 1, 2026, and the Chief Scientific Officer will present Phase 2 data at the ARVO Annual Meeting in Denver in early May.
The company’s lead drug, urcosimod, is an investigational therapy for neuropathic corneal pain (NCP) and inflammatory eye diseases. It is the first therapy to receive an IND specifically for NCP and has Fast Track designation from the U.S. FDA. OKYO reports clinically meaningful pain reduction and quality-of-life improvement in an 18-patient randomized, placebo-controlled, double-masked Phase 2 NCP trial, and statistically significant results in an earlier 240-patient Phase 2 dry eye disease trial. OKYO plans to start a 150-patient Phase 2b/3 multiple-dose NCP study in the first half of the year.
OKYO Pharma is highlighting progress for its lead eye therapy, urcosimod, around the 2026 ASCRS meeting in Washington, DC. The company will convene a Scientific Advisory Board of leading ophthalmology experts to review Phase 2 clinical data and guide the next clinical program.
In parallel, principal investigator Dr. Pedram Hamrah will present Phase 2 proof-of-concept results on urcosimod in neuropathic corneal pain, covering efficacy and safety. Urcosimod holds an IND and FDA Fast Track designation for this indication, and OKYO plans a 150-patient Phase 2b/3 multiple-dose study in the first half of 2026.
OKYO Pharma filed a report highlighting an insider share purchase by Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest. Panetta Partners acquired 10,119 ordinary shares on Nasdaq at $1.59, bringing Cerrone’s total holding to 10,526,416 shares.
The filing also reiterates OKYO’s clinical focus on neuropathic corneal pain and inflammatory eye diseases. Its lead candidate, urcosimod, has shown pain reduction in Phase 2 studies, and the company plans to start a ~150‑subject Phase 2b/3 multiple‑dose NCP study in the first half of this year.
OKYO Pharma Limited filed a report noting that Non-Executive Director John Brancaccio acquired 5,000 ordinary shares on Nasdaq at $1.61 per share, increasing his holding to 31,201 shares. The company also highlights urcosimod, its lead drug candidate for neuropathic corneal pain and inflammatory eye diseases, which has shown anti-inflammatory and pain-reducing activity in preclinical models. OKYO recently reported positive pain-reduction data from a randomized, placebo-controlled, double-masked Phase 2a trial in 18 neuropathic corneal pain subjects and earlier significant pain reduction in a 240-subject Phase 2 dry eye disease trial. The company plans to start an approximately 150-subject Phase 2b/3 multiple-dose study of urcosimod in neuropathic corneal pain in the first half of the year.